Skip to content
15% off your first order15% off your first order

CJC-1295 vs Sermorelin

CJC-1295 and Sermorelin are both growth-hormone-releasing hormone (GHRH) analogs that act on the pituitary GHRH receptor. CJC-1295 without DAC, also called modified GRF 1-29, is described in research as a short-acting analog; lacking a drug affinity complex keeps its action brief, which research associates with preserving natural pulsatile growth hormone release. Its human evidence is early, drawn mainly from reviews, anti-doping detection work, and a small trial of the long-acting DAC form. Published reviews describe clinical use of Sermorelin in diagnosing and treating idiopathic growth hormone deficiency in children, and it continues to be discussed in research on adult-onset growth hormone insufficiency and other areas.